Stock listing
NASDAQ:RNXT RenovoRx, Inc. Stock
Home listing (NASDAQ) of RenovoRx, Inc.
Follow RenovoRx, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:RNXT
$0.942 USD -0.178 (-15.9%)
Close on Nov 20, 2026
- Day range
- $0.940 – $1.050 USDNov 20, 2026
- Volume
- 477,326 sharesNov 20, 2026
- Market cap
- $45.45M USDAt the close on Nov 20, 2026 · price × 48.25M shares outstanding
- 52-week range
- $0.770 – $2.590 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.38M USDMedian day 490,059 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:RNXT · Home | $0.942 USD | -0.178 (-15.9%) | 477,326 | $1.030 | $1.050 | $0.940 | $1.120 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RNXT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.942 | -0.178 | -15.9% | $1.030 | $1.050 | $0.940 | 477,326 | |
| $1.120 | +0.080 | +7.7% | $1.050 | $1.160 | $1.040 | 841,213 | |
| $1.040 | +0.085 | +8.9% | $0.990 | $1.060 | $0.960 | 490,059 | |
| $0.955 | -0.085 | -8.2% | $1.010 | $1.059 | $0.900 | 824,472 | |
| $1.040 | -0.120 | -10.3% | $1.180 | $1.195 | $1.040 | 815,137 | |
| $1.160 | -0.060 | -4.9% | $1.210 | $1.220 | $1.100 | 466,138 | |
| $1.220 | +0.040 | +3.4% | $1.150 | $1.260 | $1.123 | 256,004 | |
| $1.180 | 0.000 | 0.0% | $1.180 | $1.224 | $1.110 | 252,735 | |
| $1.180 | +0.050 | +4.4% | $1.160 | $1.540 | $1.092 | 844,358 | |
| $1.130 | -0.060 | -5.0% | $1.050 | $1.205 | $0.880 | 1,845,119 | |
| $1.190 | -0.120 | -9.2% | $1.300 | $1.330 | $1.150 | 341,805 | |
| $1.310 | +0.020 | +1.6% | $1.330 | $1.370 | $1.270 | 217,508 | |
| $1.290 | +0.030 | +2.4% | $1.250 | $1.330 | $1.240 | 276,187 | |
| $1.260 | -0.070 | -5.3% | $1.310 | $1.335 | $1.230 | 304,275 | |
| $1.330 | -0.160 | -10.7% | $1.490 | $1.497 | $1.300 | 376,393 | |
| $1.490 | +0.065 | +4.6% | $1.430 | $1.510 | $1.430 | 386,822 | |
| $1.425 | +0.035 | +2.5% | $1.420 | $1.460 | $1.350 | 172,958 | |
| $1.390 | +0.080 | +6.1% | $1.330 | $1.430 | $1.300 | 289,369 | |
| $1.310 | +0.020 | +1.6% | $1.300 | $1.340 | $1.270 | 181,717 | |
| $1.290 | +0.020 | +1.6% | $1.250 | $1.310 | $1.250 | 284,000 | |
| $1.270 | +0.040 | +3.3% | $1.230 | $1.280 | $1.220 | 225,700 | |
| $1.230 | +0.030 | +2.5% | $1.200 | $1.290 | $1.180 | 403,500 | |
| $1.200 | +0.040 | +3.4% | $1.160 | $1.240 | $1.160 | 264,600 | |
| $1.160 | +0.020 | +1.8% | $1.150 | $1.200 | $1.140 | 288,500 | |
| $1.140 | -0.050 | -4.2% | $1.210 | $1.220 | $1.140 | 276,800 | |
| $1.190 | +0.070 | +6.2% | $1.110 | $1.215 | $1.110 | 328,600 | |
| $1.120 | -0.030 | -2.6% | $1.130 | $1.155 | $1.090 | 624,400 | |
| $1.150 | -0.100 | -8.0% | $1.243 | $1.270 | $1.135 | 942,400 | |
| $1.250 | -0.030 | -2.3% | $1.260 | $1.320 | $1.250 | 254,100 | |
| $1.280 | -0.050 | -3.8% | $1.320 | $1.350 | $1.250 | 798,200 | |
| $1.330 | -0.040 | -2.9% | $1.330 | $1.370 | $1.310 | 438,600 | |
| $1.370 | -0.020 | -1.4% | $1.350 | $1.410 | $1.275 | 589,800 | |
| $1.390 | -0.080 | -5.4% | $1.510 | $1.570 | $1.370 | 620,900 | |
| $1.470 | -0.110 | -7.0% | $1.580 | $1.610 | $1.430 | 618,000 | |
| $1.580 | +0.030 | +1.9% | $1.570 | $1.610 | $1.550 | 269,400 | |
| $1.550 | -0.010 | -0.6% | $1.570 | $1.590 | $1.500 | 404,000 | |
| $1.560 | -0.010 | -0.6% | $1.570 | $1.640 | $1.540 | 397,200 | |
| $1.570 | +0.020 | +1.3% | $1.570 | $1.590 | $1.510 | 370,000 | |
| $1.550 | -0.110 | -6.6% | $1.650 | $1.650 | $1.500 | 876,700 | |
| $1.660 | -0.020 | -1.2% | $1.690 | $1.725 | $1.645 | 490,600 | |
| $1.680 | +0.050 | +3.1% | $1.610 | $1.700 | $1.530 | 630,000 | |
| $1.630 | -0.070 | -4.1% | $1.700 | $1.800 | $1.600 | 765,000 | |
| $1.700 | +0.030 | +1.8% | $1.700 | $1.730 | $1.670 | 383,900 | |
| $1.670 | -0.020 | -1.2% | $1.690 | $1.740 | $1.630 | 482,500 | |
| $1.690 | -0.040 | -2.3% | $1.740 | $1.750 | $1.670 | 566,800 | |
| $1.730 | +0.180 | +11.6% | $1.600 | $1.770 | $1.580 | 635,100 | |
| $1.550 | -0.170 | -9.9% | $1.730 | $1.730 | $1.550 | 1,035,400 | |
| $1.720 | +0.030 | +1.8% | $1.692 | $1.730 | $1.600 | 1,032,200 | |
| $1.690 | -0.070 | -4.0% | $1.750 | $1.850 | $1.660 | 577,900 | |
| $1.760 | -0.010 | -0.6% | $1.770 | $1.820 | $1.670 | 1,164,400 | |
| $1.770 | -0.225 | -11.3% | $1.970 | $1.990 | $1.710 | 1,636,800 | |
| $1.995 | -0.205 | -9.3% | $2.150 | $2.300 | $1.935 | 1,726,900 | |
| $2.200 | -0.190 | -7.9% | $2.310 | $2.345 | $2.151 | 1,207,100 | |
| $2.390 | +0.020 | +0.8% | $2.350 | $2.540 | $2.280 | 2,090,200 | |
| $2.370 | -0.150 | -6.0% | $2.520 | $2.520 | $1.980 | 3,818,100 | |
| $2.520 | +0.410 | +19.4% | $2.140 | $2.590 | $2.140 | 4,134,700 | |
| $2.110 | +0.180 | +9.3% | $1.910 | $2.200 | $1.830 | 3,308,300 | |
| $1.930 | +0.260 | +15.6% | $1.735 | $1.970 | $1.650 | 3,294,200 | |
| $1.670 | +0.190 | +12.8% | $1.480 | $1.679 | $1.471 | 1,054,800 | |
| $1.480 | -0.010 | -0.7% | $1.470 | $1.550 | $1.430 | 427,900 | |
| $1.490 | +0.070 | +4.9% | $1.410 | $1.550 | $1.385 | 763,800 | |
| $1.420 | +0.170 | +13.6% | $1.300 | $1.560 | $1.270 | 1,345,430 | |
| $1.250 | -0.070 | -5.3% | $1.330 | $1.358 | $1.240 | 264,048 | |
| $1.320 | 0.000 | 0.0% | $1.300 | $1.325 | $1.250 | 233,100 | |
| $1.320 | +0.005 | +0.4% | $1.290 | $1.350 | $1.230 | 381,200 |
- Ticker
- NASDAQ:RNXT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 20, 2026
Initial Statement of Beneficial Ownership (Form 3)
Latest earnings call · Nov 5, 2026
RenovoRx (NASDAQ:RNXT) Q3 2026 Earnings Call
Replay and transcript
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 28 slides
Latest news
Initial Statement of Beneficial Ownership (Form 3)
Nov 20, 2026
Closed $0.942 (-15.9%) on Nov 20, 2026
RenovoRx Appoints Interventional Oncology Medtech Leader Richard Stark to its Board of Directors
Nov 19, 2026
Closed $0.942 (-15.9%) on Nov 20, 2026
RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million
Nov 5, 2026
Closed $1.13 (-5.0%) on Nov 6, 2026
RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum
Oct 28, 2026
Closed $1.43 (+2.5%) on Oct 28, 2026
RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
Oct 22, 2026
Closed $1.27 (+3.3%) on Oct 22, 2026
RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
Oct 7, 2026
Closed $1.37 (-1.4%) on Oct 7, 2026
RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer
Oct 1, 2026
Closed $1.55 (-0.6%) on Oct 1, 2026
RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th
Sep 2, 2026
Closed $2.52 (+19.4%) on Sep 2, 2026
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
Aug 25, 2026
Closed $1.42 (+13.6%) on Aug 25, 2026
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
Aug 21, 2026
Closed $1.32 (0.0%) on Aug 21, 2026
RenovoRx, Inc. on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 44 in the last 12 months · 138 in all · newest Nov 20, 2026 · oldest 2021
- Calls
- 7 calls with a replay · 7 with a transcript · latest Nov 5, 2026
- Decks
- 12 decks · latest November 2026
Where RenovoRx, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:RNXT · Home listing · This page | NASDAQ | United States | USD |
| BOATS:RNXT | BOATS | United States | USD |
Valuation
EV/sales 12.7× against a median of 2.6×: the highest of 10 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $35.27M USD
- P/E
- Loss
- EV/sales
- 12.7×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 4.9×
- Gross margin
- 84.0%
- Operating margin
- −489.1%
- Net margin
- −469.0%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.71
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| RenovoRx, Inc. · NASDAQ:RNXT | US$45.45M | US$35.27M | n/a | 12.7× | n/a | 4.9× | −469.0% | 0.0× | 1.71 |
| Medimaging Integrated Solution Inc. · TWSE:6796 | US$48.04M | US$43.05M | 111× | 2.1× | 28.6× | 1.9× | 2.1% | 0.5× | n/a |
| Conexeu Sciences Inc. · NASDAQ:CNXU | US$47.79M | US$45.82M | n/a | n/a | n/a | 8.2× | n/a | 0.0× | 2.08 |
| Microbot Medical Inc. · NASDAQ:MBOT | US$45.67M | −US$16.16M | n/a | −38.6× | n/a | 0.7× | n/a | 0.0× | 1.82 |
| Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. · BIST:ONCSM | US$45.28M | US$45.31M | 31.7× | 2.9× | 7.5× | 4.5× | 9.0% | 0.1× | n/a |
| Somnomed Limited · ASX:SOM | US$45.09M | US$37.33M | n/a | 0.5× | 8.7× | 1.4× | −2.3% | 0.1× | n/a |
| Bactiguard Holding AB · OMXSTO:BACTI_B | US$45.09M | US$54.74M | 76.6× | 2.6× | 12.5× | 1.5× | 2.8% | 0.5× | n/a |
| Nuo Therapeutics Inc · OTC:AURX | US$44.38M | US$44.30M | n/a | 7.3× | n/a | n/a | −31.5% | n/a | 0.73 |
| Ortoma AB Class B · OMXSTO:ORT_B | US$44.22M | US$38.08M | n/a | 11.7× | n/a | 2.6× | −197.7% | 0.0× | n/a |
| BrainCool AB · OMXSTO:BRAIN | US$43.26M | US$39.04M | n/a | 9.8× | n/a | 2.8× | −84.7% | 0.0× | n/a |
| Corentec Co., Ltd. · KRX:104540 | US$42.84M | US$24.22M | 8.5× | 0.3× | 2.3× | 0.7× | 6.4% | 0.0× | n/a |
| Median of the others | US$45.09M | US$41.05M | 54.1× | 2.6× | 8.7× | 1.9× | −0.1% | 0.0× | 1.82 |
Forecasts
4 strong buy · Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.
- Price target
- 7.25 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.27 · 1 analyst
- Revenue, year to Dec 2026
- 3.86M · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Shaun R. Bagai | Director and Chief Executive Officer |
| Mark Voll | Chief Financial Officer |
| Ronald B. Kocak | Vice President of Finance and Controller |
| Tom Kelly | VP of Operations and Quality |
| Leesa Gentry | Chief Clinical Officer |
| Ramtin Agah | Chairman, Chief Medical Officer, and Founder |
Board
| Director | Role |
|---|---|
| Ramtin Agah | Chairman, Chief Medical Officer, and Founder |
| Angela Macfarlane | Director |
| Laurence J. Marton | Director |
| Richard Stark | Director |
| Robert J. Spiegel | Director |
| Shaun R. Bagai | Director and Chief Executive Officer |
| Una S. Ryan | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| RenovoRx (NASDAQ:RNXT) Q3 2026 Earnings Call | Thu, Nov 05, 2026 · 4:30 PM ET | Replay |
| RenovoRx (NASDAQ:RNXT) Q2 2026 Earnings Call | Wed, Aug 12, 2026 · 4:30 PM ET | Replay |
| RenovoRx (NASDAQ:RNXT) Q1 2026 Earnings Call | Thu, May 14, 2026 · 4:30 PM ET | Replay |
| RenovoRx (NASDAQ:RNXT) Q4 2025 Earnings Call | Mon, Mar 30, 2026 · 4:30 PM ET | Replay |
| RenovoRx (NASDAQ:RNXT) Q3 2025 Earnings Call | Thu, Nov 13, 2025 · 4:30 PM ET | Replay |
| RenovoRx (NASDAQ:RNXT) Q2 2025 Earnings Call | Thu, Aug 14, 2025 · 4:30 PM ET | Replay |
| RenovoRx (NASDAQ:RNXT) Q1 2025 Earnings Call | Thu, May 15, 2025 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | −5.0% |
| Q2 2026 | Aug 12, 2026 · After close | +12.5% |
| Q1 2026 | May 14, 2026 · After close | −4.1% |
| Q3 2025 | Nov 13, 2025 · After close | −23.0% |
| Q2 2025 | Aug 14, 2025 · After close | −22.9% |
| Q1 2025 | May 15, 2025 · After close | +6.3% |
| Q3 2024 | Nov 13, 2024 · After close | 0.0% |
| Q2 2024 | Aug 13, 2024 · After close | −3.5% |
| Q1 2024 | Apr 1, 2024 · After close | −6.1% |
| Q4 2023 | Mar 19, 2024 · After close | +0.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2023 | Nov 13, 2023 · After close | −28.4% |
| Q2 2023 | Aug 16, 2023 · After close | +7.6% |
| Q1 2023 | May 12, 2023 · After close | +10.9% |
| Q4 2022 | Mar 2, 2023 · Before open | −3.5% |
| Q3 2022 | Nov 14, 2022 · Before open | +2.7% |
| Q2 2022 | Aug 12, 2022 · After close | +1.5% |
| Q1 2022 | May 13, 2022 · After close | 0.0% |
| Q4 2021 | Mar 30, 2022 · Before open | −1.3% |
| Quarter to Sep 30, 2021 | Nov 15, 2021 · After close | −12.9% |
| Quarter to Jun 30, 2021 | Aug 27, 2021 · Before open | +6.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 28 slides | November 2026 |
| Investor Presentation (September 2026) | Investor deck | 30 slides | September 2026 |
| Q2 2026 Earnings Presentation | Earnings | 31 slides | Aug 12, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 30 slides | May 14, 2026 |
| Technical Presentation (February 2025) | Technical | 17 slides | February 2025 |
| SIR 2024 | Conference | 13 slides | Mar 17, 2024 |
| Technical Presentation (2023) | Technical | 19 slides | 2023 |
| Investor Presentation (March 2022) | Investor deck | 21 slides | Mar 14, 2022 |
| MCI Pancreas Symposium 2021 | Conference | 34 slides | November 2021 |
| Technical Presentation (June 2020) | Technical | 15 slides | June 2020 |
All 12 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| AHPBA 2017 | Conference | 20 slides | July 2017 |
| Technical Presentation (April 2017) | Technical | 20 slides | Apr 2, 2017 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$12.1M raised · US$1.05 a share · Titan Partners Group, a division of American Capital Partners Dealers: Titan Partners Group, a division of American Capital Partners (lead) Use of proceeds: Working capital and general corporate purposes, including the Phase III TIGeR-PaC study and commercial sales and marketing for RenovoCath | Feb 11, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$9.00 a unit on Aug 25, 2021.
- Price
- US$9.00 a unit
- Units offered
- 1,850,000 units
- Offering size
- US$16.6 million
- Underwriters' option
- Up to 277,500 more units
- Listing
- RNXT on the Nasdaq Capital Market
- Underwriters
- Roth Capital Partners, Maxim Group LLC · In the order on the cover
- Units delivered
- On or about Aug 30, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Apr 2, 2021 |
| Filed publicly | Jul 21, 2021 |
| Amended 4 times | Newest Aug 25, 2021 |
| Shares registered with an exchange | Aug 11, 2021 |
| Declared effective by the SEC | Aug 25, 2021 |
| Final prospectus, with the price | Aug 27, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Aug 27, 2021 |
| EFFECT · Notice that a registration is effective | Aug 25, 2021 |
| CORRESP · Letter to the SEC | Aug 25, 2021 |
| CORRESP · Letter to the SEC | Aug 25, 2021 |
| S-1/A · Registration statement, amended | Aug 25, 2021 |
| CORRESP · Letter to the SEC | Aug 24, 2021 |
| CERT · Exchange's certificate of listing | Aug 24, 2021 |
| CORRESP · Letter to the SEC | Aug 20, 2021 |
| CORRESP · Letter to the SEC | Aug 20, 2021 |
| S-1/A · Registration statement, amended | Aug 19, 2021 |
All 26 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Aug 12, 2021 |
| S-1/A · Registration statement, amended | Aug 12, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Aug 11, 2021 |
| CORRESP · Letter to the SEC | Aug 10, 2021 |
| CORRESP · Letter to the SEC | Aug 10, 2021 |
| S-1/A · Registration statement, amended | Aug 5, 2021 |
| CORRESP · Letter to the SEC | Aug 5, 2021 |
| UPLOAD · Letter from the SEC | Jul 29, 2021 |
| S-1 · Registration statement | Jul 21, 2021 |
| DRSLTR · Letter to the SEC with a draft | Jun 15, 2021 |
| DRS/A · Draft registration statement, amended | Jun 15, 2021 |
| UPLOAD · Letter from the SEC | May 28, 2021 |
| DRSLTR · Letter to the SEC with a draft | May 12, 2021 |
| DRS/A · Draft registration statement, amended | May 12, 2021 |
| UPLOAD · Letter from the SEC | May 3, 2021 |
| DRS · Draft registration statement | Apr 2, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Aug 27, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.12M | 43.0K | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 327.0K | 0 | 0 | 6.00K | 9.00K | ||
| Gross profit | 796.0K | 43.0K | 0 | -6.00K | -9.00K | ||
| Research and development | 6.27M | 6.03M | 5.67M | 4.30M | 3.04M | 2.39M | 3.00M |
| Selling, general and administrative | 7.04M | 4.99M | 5.73M | 5.65M | 2.63M | 818.0K | 899.0K |
| Operating income | -12.5M | -11.0M | -11.4M | -9.95M | -5.67M | -3.20M | -3.90M |
| Depreciation and amortization | 2.00M | 0 | 6.00K | 6.00K | 9.00K | 3.20M | 9.00K |
| EBITDA | -10.5M | -11.0M | -11.4M | -9.94M | -5.66M | 0 | -3.89M |
| Interest expense | 384.0K | 108.0K | 57.0K | 904.0K | 590.0K | 0 | |
| Income before tax | -11.2M | -8.75M | -10.2M | -9.89M | -6.32M | -3.80M | -3.84M |
| Income tax | 2.00K | -8.81M | -6 | -118.0K | 772.0K | 587.0K | -63.0K |
| Net income | -11.2M | -8.81M | -10.2M | -9.89M | -6.32M | -3.80M | -3.84M |
| Earnings per share, basic | -0.32 | -0.40 | -0.99 | -1.09 | -1.21 | -1.72 | -0.22 |
| Earnings per share, diluted | -0.32 | -0.40 | -0.99 | -1.09 | -1.21 | -1.72 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 7.02M | 7.15M | 1.17M | 4.39M | 15.2M | 1.79M | 2.10M |
| Short-term investments | 0 | 2.05M | 0 | ||||
| Receivables | 139.0K | 43.0K | 0 | ||||
| Inventory | 189.0K | 0 | |||||
| Current assets | 7.89M | 7.83M | 1.47M | 7.26M | 16.3M | 1.91M | 2.27M |
| Property, plant and equipment | 12.0K | 12.0K | 6.00K | ||||
| Total assets | 8.10M | 8.12M | 1.47M | 7.26M | 16.3M | 1.91M | 2.27M |
| Accounts payable | 799.0K | 586.0K | 561.0K | 534.0K | 525.0K | 162.0K | 538.0K |
| Current liabilities | 1.96M | 1.91M | 1.18M | 1.10M | 938.0K | 4.10M | 805.0K |
| Long-term debt | 23.0K | ||||||
| Total debt | 212.0K | 278.0K | 2.79M | 12.4M | |||
| Total liabilities | 2.67M | 3.64M | 4.47M | 1.10M | 938.0K | 4.12M | 805.0K |
| Shareholders' equity | 5.42M | 4.48M | 3.00M | 6.16M | 15.3M | -14.7M | 1.47M |
| Shares outstanding | 36.6M | 24.0M | 10.7M | 9.10M | 8.93M | 2.23M | 17.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -11.0M | -9.13M | -10.3M | -8.81M | -5.92M | -3.53M | -3.35M |
| Capital spending | -2.00K | -12.0K | 0 | 0 | -15.0K | -15.0K | -15.0K |
| Free cash flow | -11.0M | -9.14M | -10.3M | -8.81M | -5.93M | -3.53M | -3.35M |
| Cash from investing | -2.00K | -12.0K | 2.03M | -2.03M | -15.0K | -15.0K | -1.00K |
| Cash from financing | 10.8M | 15.1M | 5.01M | 42.0K | 19.3M | 3.20M | 3.20M |
| Change in cash | -130.0K | 5.98M | -3.22M | -10.8M | 13.4M | -329.0K | -3.35M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 20, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 20, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 6, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| RW · Request to withdraw a registration | Oct 16, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 20, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K/A · Current report, amended | Aug 13, 2026 | Results | SEC |
| 8-K · Current report | Aug 12, 2026 | Current report | SEC |
| 8-K · Current report | Aug 4, 2026 | Current report | SEC |
| 8-K · Current report | Jul 2, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Jun 30, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 30, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 10-K/A · Annual report, amended | May 15, 2026 | Annual report | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Apr 28, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Apr 27, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 27, 2026 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Apr 23, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 22, 2026 | Other filings | SEC |
| S-3 · Registration statement | Apr 16, 2026 | Offer document | SEC |
| D | Apr 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 7, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 31, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 30, 2026 | Results | SEC |
| 10-K · Annual report | Mar 30, 2026 | Annual report | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 3/A · Initial statement of ownership, amended | Mar 27, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 27, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Mar 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 24, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 23, 2026 | Material contract | SEC |
| 8-K · Current report | Feb 6, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 2, 2026 | Current report | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 14, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Nov 14, 2025 | Offer document | SEC |
| S-3 · Registration statement | Nov 14, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 10, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Aug 28, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 26, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| CORRESP · Letter to the SEC | Aug 13, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 29, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 18, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 10, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jun 27, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 25, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | May 8, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 6, 2025 | Insider trade | SEC |
| DEF 14A · Proxy statement | Apr 30, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 1, 2025 | Results | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| NT 10-K · Late filing notice | Mar 31, 2025 | Explanation request | SEC |
| 8-K · Current report | Feb 10, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Feb 10, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Feb 6, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 25, 2024 | Current report | SEC |
| 8-K · Current report | Aug 16, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jun 7, 2024 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | May 13, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | May 13, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | May 10, 2024 | Quarterly report | SEC |
| 424B3 · Prospectus | May 10, 2024 | Offer document | SEC |
| 424B3 · Prospectus | May 10, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 8, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 8, 2024 | Other filings | SEC |
| 8-K · Current report | May 3, 2024 | Management or board change | SEC |
| UPLOAD · Letter from the SEC | May 1, 2024 | Other filings | SEC |
| DEF 14A · Proxy statement | Apr 30, 2024 | Meeting notice | SEC |
| S-3 · Registration statement | Apr 26, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Apr 24, 2024 | Other filings | SEC |
| D | Apr 22, 2024 | Other filings | SEC |
| S-3 · Registration statement | Apr 19, 2024 | Offer document | SEC |
| 8-K · Current report | Apr 18, 2024 | Current report | SEC |
| 8-K · Current report | Apr 16, 2024 | Current report | SEC |
| 8-K · Current report | Apr 15, 2024 | Financing | SEC |
| S-8 · Registration statement for employee plans | Apr 12, 2024 | Offer document | SEC |
| 8-K · Current report | Apr 9, 2024 | Material contract | SEC |
| 10-K · Annual report | Apr 1, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 14, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Mar 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 8, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 23, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Feb 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 9, 2024 | Management or board change | SEC |
| D | Feb 9, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jan 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 29, 2024 | Material contract | SEC |
| 4 · Change in ownership | Jan 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 2, 2024 | Current report | SEC |
| 8-K · Current report | Dec 18, 2023 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Nov 27, 2023 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Nov 17, 2023 | Meeting notice | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2023 | Current report | SEC |
| 4 · Change in ownership | Oct 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 8, 2023 | Current report | SEC |
| 8-K · Current report | Aug 25, 2023 | Current report | SEC |
| 8-K · Current report | Aug 17, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 16, 2023 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Aug 15, 2023 | Explanation request | SEC |
| 8-K · Current report | Jun 29, 2023 | Current report | SEC |
| 8-K · Current report | Jun 9, 2023 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | May 22, 2023 | Other filings | SEC |
| 424B3 · Prospectus | May 19, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 17, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 16, 2023 | Other filings | SEC |
| 8-K · Current report | May 15, 2023 | Results | SEC |
| S-3 · Registration statement | May 12, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | May 12, 2023 | Quarterly report | SEC |
| DEF 14A · Proxy statement | May 1, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 27, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 27, 2023 | Insider trade | SEC |
| 8-K · Current report | Apr 27, 2023 | Management or board change | SEC |
| 8-K · Current report | Apr 3, 2023 | Material contract | SEC |
| 424B5 · Prospectus | Apr 3, 2023 | Offer document | SEC |
| S-8 POS | Mar 31, 2023 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 31, 2023 | Offer document | SEC |
| 10-K · Annual report | Mar 31, 2023 | Annual report | SEC |
| 4 · Change in ownership | Mar 29, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 29, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 29, 2023 | Insider trade | SEC |
| 8-K · Current report | Mar 2, 2023 | Results | SEC |
This page holds 200 of 297 filings. Open Filings
Cap table
Built by 6ix from RenovoRx, Inc.’s releases · as of Oct 30, 2026
- Common shares
- 48,250,592
- Fully diluted
- 48,250,592
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 48,250,592 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 48,250,592 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Robert J. Spiegel Other companies: Ernexa Therapeutics Inc. (Director · Since at least Sep 14, 2026); Geron Corporation (Director · Since at least Sep 29, 2017); Athenex Inc (Director · Aug 4, 2020 – Apr 21, 2023 · Past); Ayala Pharmaceuticals Inc (Director · May 7, 2020 – Jan 19, 2023 · Past); Bio Green Med Solution, Inc. (Director · Sep 6, 2018 – Jun 30, 2023 · Past); PDS Biotechnology Corporation (Director · Jun 19, 2018 – Mar 15, 2019 · Past); Sucampo Pharmaceuticals Inc (Director · Feb 13, 2018 – Feb 13, 2018 · Past) | Director · Since at least Apr 25, 2023 |
| James M. Ahlers Other companies: Cue Biopharma, Inc. (Chief Financial Officer · Since at least Jul 30, 2026); Intensity Therapeutics, Inc. (Executive Vice President · Since at least Jun 29, 2023) | Chief Financial Officer · Jul 15, 2022 – Jul 15, 2022 · Past |
| Laurence J. Marton Other companies: Matternet Inc (Director · Since at least May 22, 2026) | Director · Since at least Apr 8, 2025 |
| Angela Macfarlane | Director · Since at least Nov 20, 2026 |
| Angela Nelms | Chief Operating Officer · Sep 19, 2022 – Jan 19, 2024 · Past |
| Leesa Gentry | Chief Clinical Officer · Since at least Mar 1, 2024 |
| Mark Voll | Chief Financial Officer · Since at least Feb 5, 2026 |
| Phil Stocton | Vice President of Sales and Market Development · Aug 14, 2025 – Nov 20, 2026 · Past |
| Ramtin Agah | Chairman, Chief Medical Officer, and Founder · Since at least Feb 27, 2026 |
| Richard Stark | Director · Since at least Nov 19, 2026 |
All 14 people
| Person | Seat |
|---|---|
| Ronald B. Kocak | Vice President of Finance and Controller · Since at least Feb 5, 2026 |
| Shaun R. Bagai | Director and Chief Executive Officer · Since at least Aug 25, 2021 |
| Tom Kelly | VP of Operations and Quality · Since at least Nov 20, 2026 |
| Una S. Ryan | Director · Since at least Mar 3, 2022 |
Log in to ask 6ix AI your own questions about RenovoRx, Inc.